Metabolomic Profiling of Novel Mediators of Vascular Function

This study has been terminated.

(Study enrollment was no adequate.)

Sponsor:

ClinicalTrials.gov Identifier:

NCT00762242

First Posted: September 30, 2008

Last Update Posted: December 12, 2016

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Joshua A. Beckman, MD, Brigham and Women's Hospital

Purpose

The purpose of this study is to identify and characterize specific chemicals and metabolic pathways that change with forearm ischemia. These changes will be compared with forearm blood flow and flow-mediated vasodilation of the brachial artery.

Condition	Intervention
Type 2 Diabetes Mellitus	Procedure: blood sampling and brachial artery ultrasound


Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective
Official Title:	Metabolomic Profiling of Novel Mediators of Vascular Function

Further study details as provided by Joshua A. Beckman, MD, Brigham and Women's Hospital:

Primary Outcome Measures:

change from baseline (pre-forearm ischemia) in circulating metabolites compared with post-ischemic forearm measurements [ Time Frame: pre/post 5 minute ischemic stimulus ]

Biospecimen Retention: Samples Without DNA

plasma samples for assays of novel biomarkers


Enrollment:	48
Study Start Date:	May 2007
Estimated Study Completion Date:	February 2018
Estimated Primary Completion Date:	February 2018 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 Blood sampling and brachial artery ultrasound	Procedure: blood sampling and brachial artery ultrasound Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes) Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery. Following completion of blood sampling, an additional "resting" image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation.

Groups/Cohorts

Assigned Interventions

Blood sampling and brachial artery ultrasound

Procedure: blood sampling and brachial artery ultrasound

Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)

Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.

Following completion of blood sampling, an additional "resting" image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

community sample

Criteria

Inclusion Criteria:

Adults age 18 or older
Type 2 diabetes mellitus

Exclusion Criteria:

Type 1 diabetes mellitus
Type 2 diabetics taking insulin, thiazolidinediones (rosiglitazone or pioglitazone), an amylin analog (Symlin [pramlintide]), or incretin mimetics (Byetta [exenatide])
Pregnancy
Uncontrolled hypertension, > 180/100 mmHg

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00762242

Locations


United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Brigham and Women's Hospital

Investigators


Principal Investigator:	Joshua A. Beckman, M.D.	Brigham and Women's Hospital

More Information


Responsible Party:	Joshua A. Beckman, MD, Associate Professor of Medicine, Harvard Medical School, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:	NCT00762242 History of Changes
Other Study ID Numbers:	2007P-000669
First Submitted:	September 26, 2008
First Posted:	September 30, 2008
Last Update Posted:	December 12, 2016
Last Verified:	December 2016

Keywords provided by Joshua A. Beckman, MD, Brigham and Women's Hospital:


metabolomics flow-mediated vasodilation

Additional relevant MeSH terms:


Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases

To Top